Tag:

Diabetes

Latest Headlines

Latest Headlines

Health Diagnostic Laboratory helps find promising predictive diabetes biomarkers

Virginia's Health Diagnostic Laboratory and the University of Utah are zeroing in on fasting levels of simple blood biomarkers that may enable quicker diagnosis of diabetes risks than current standards of care.

Regeneron nabs FDA 'breakthrough' tag for new Eylea use in diabetics

Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.

As America's diabetes problem grows, so do prices on Lilly's Humulin

Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.

UPDATED: Setback forces Novo Nordisk to abandon anti-inflammatory R&D work, affecting 400 staffers

Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.

Merck taps celeb chef to deliver diabetes message to Hispanics

Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck is launching a similar campaign aimed at the Hispanic community, which is disproportionately affected by the disease.

Diabetes culprit may be a single enzyme

Scientists have linked a single enzyme to the development of diabetes, a finding that could help develop new treatments for the more than 120 million Americans that have diabetes or pre-diabetes.

Can third to market be a charm for Lilly, Boehringer diabetes med Jardiance?

Without the safety concerns that plague its competitors, Jardiance may be able to make a splash.

Scripps researchers uncover new signaling pathway in brown fat cells

Investigators at The Scripps Research Institute discovered a signaling pathway that switches on a calorie-burning phenomenon in cells.

FDA comes around on Boehringer, Lilly's diabetes med Jardiance

The FDA is changing its tune on Jardiance, a Boehringer Ingelheim diabetes med it hasn't been so keen on in the past. After rejecting the drug in the face of a manufacturing issue, the agency Friday gave it approval to treat Type 2 diabetes.

Top Sanofi U.S. exec departs amid struggles in diabetes franchise

According to an internal memo obtained by The Wall Street Journal blog Pharmalot, Whitaker is leaving for "another opportunity."